Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HITI.V
SELLREMOVEHigh Tide Inc. · Healthcare · Canada · $203M · Avg Vol: $128K/d
High Tide operates a discount club model in the cannabis retail space, which shows some Nick Sleep-style scale economics. However, the cannabis sector lacks a durable economic moat, faces persistent regulatory headwinds, and does not align with our high-conviction macro themes for the next 18 months.
COMPANY DESCRIPTION
High Tide Inc. is a leading, vertically integrated cannabis consumer technology and retail company operating across Canada, the United States, and Europe. The company operates a dominant brick-and-mortar retail footprint under the Canna Cabana banner, supported by a highly successful discount club loyalty model. High Tide's competitive moat is its proprietary data analytics, extensive e-commerce platforms, and a highly scalable, recurring-revenue retail ecosystem.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 251.8M | 344.2M | 368.6M | 419.2M | 18.5% |
| EPS | -0.80 | -0.37 | -0.04 | -0.44 | — |
| Shares | 71.0M | 75.3M | 80.8M | 87.5M | +23.2% |
| Debt | 49.3M | 51.2M | 52.7M | 105.1M | 28.7% |
| Equity | 110.3M | 92.8M | 101.1M | 61.8M | -17.6% |
| Op CF | 3.2M | 14.6M | 25.1M | 16.8M | 74.5% |
| Inv CF | -6.1M | -4.0M | -7.8M | -15.7M | — |
| Fin CF | 10.7M | -6.5M | -5.5M | 0.1M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HITI.V are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HITI.V | High Tide Inc.(you) | $203M | 30 | SELL |
| PCRX.V | PharmaCorp Rx Inc. | $65M | 54 | HOLD |
| ACB | Aurora Cannabis Inc. | $181M | 30 | SELL |
| OGI | Organigram Global Inc. | $138M | 31 | SELL |
| EDT.TO | Spectral Medical Inc. | $282M | 28 | SELL |
| PROF | Profound Medical Corp. | $251M | 24 | SELL |
| CRDL.TO | Cardiol Therapeutics Inc. | $123M | 22 | SELL |
| EPRX.TO | Eupraxia Pharmaceuticals Inc. | $415M | 26 | SELL |
| OBI.L | Ondine Biomedical Inc. | $101M | 20 | SELL |
| WEED.TO | Canopy Growth Corporation | $501M | 21 | SELL |
Peer medians: ROE -48.5% · P/E 14.3x · Gross margin 35.6%